Vyhlidal Carrie A, Rogan Peter K, Leeder J Steven
Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Medical Toxicology and Laboratory of Human Molecular Genetics, Children's Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA.
J Biol Chem. 2004 Nov 5;279(45):46779-86. doi: 10.1074/jbc.M408395200. Epub 2004 Aug 16.
The pregnane X receptor (PXR) acts as a receptor to induce gene expression in response to structurally diverse xenobiotics through binding as a heterodimer with the 9-cis retinoic acid receptor (RXR) to enhancers in target gene promoters. We identified and estimated the affinities of novel PXR/RXR binding sites in regulated genes and additional genomic targets of PXR with an information theory-based model of the PXR/RXR binding site. Our initial PXR/RXR model, the result of the alignment of 15 previously characterized binding sites, was used to scan the promoters of known PXR target genes. Sites from these genes, with information contents of >8 bits bound by PXR/RXR in vitro, were used to revise the information weight matrix; this procedure was repeated by screening for progressively weaker binding sites. After three iterations of refinement, the model was based on 48 validated PXR/RXR binding sites and has an average information content (Rsequence) of 14.43 +/- 3.21 bits. A scan of the human genome predicted novel PXR/RXR binding sites in the promoters of UGT1A3 (19.78 bits at -8040 and 16.37 bits at -6930) and UGT1A6 (12.74 bits at -9216), both of which were identified previously as targets for PXR. These sites were subsequently demonstrated to specifically bind PXR/RXR in competition electrophoretic mobility shift assays. A strong PXR site was also predicted upstream of the CASP10 gene (18.69 bits at -7872) and was validated by binding studies and reporter assays as a PXR responsive element. This suggests that the PXR-mediated response extends beyond genes involved in drug biotransformation and transport.
孕烷X受体(PXR)作为一种受体,通过与9-顺式视黄酸受体(RXR)形成异二聚体,结合到靶基因启动子中的增强子上,从而响应结构多样的外源性物质诱导基因表达。我们利用基于信息论的PXR/RXR结合位点模型,鉴定并估计了受调控基因中新型PXR/RXR结合位点以及PXR的其他基因组靶点的亲和力。我们最初的PXR/RXR模型是15个先前已表征的结合位点比对的结果,用于扫描已知PXR靶基因的启动子。来自这些基因的位点,其体外被PXR/RXR结合的信息含量>8比特,用于修正信息权重矩阵;通过筛选逐渐较弱的结合位点重复此过程。经过三次优化迭代后,该模型基于48个经过验证的PXR/RXR结合位点,平均信息含量(R序列)为14.43±3.21比特。对人类基因组的扫描预测了UGT1A3(-8040处为19.78比特,-6930处为16.37比特)和UGT1A6(-9216处为12.74比特)启动子中的新型PXR/RXR结合位点,这两个基因先前均被鉴定为PXR的靶点。随后在竞争电泳迁移率变动分析中证明这些位点能特异性结合PXR/RXR。在CASP10基因上游还预测到一个强PXR位点(-7872处为18.69比特),并通过结合研究和报告基因分析验证其为PXR反应元件。这表明PXR介导的反应超出了参与药物生物转化和转运的基因范围。